Major bleeding complications and persistence with oral anticoagulation in non‐valvular atrial fibrillation: contemporary findings in real‐life Danish patients
M Lamberts, L Staerk, JB Olesen… - Journal of the …, 2017 - Am Heart Assoc
Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …
Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the …
GYH Lip, X Pan, S Kamble, H Kawabata… - … journal of clinical …, 2016 - Wiley Online Library
Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide …
L Staerk, EL Fosbøl, GYH Lip, M Lamberts… - European heart …, 2017 - academic.oup.com
Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) are widely used
as stroke prophylaxis in non-valvular atrial fibrillation (AF), but comparative data are sparse …
as stroke prophylaxis in non-valvular atrial fibrillation (AF), but comparative data are sparse …
Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis
S Deitelzweig, C Farmer, X Luo, X Li, L Vo… - Current Medical …, 2018 - Taylor & Francis
Objective: To conduct a systematic literature review (SLR) and network meta-analysis (NMA)
of real-world studies comparing major bleeding risk among patients with non-valvular atrial …
of real-world studies comparing major bleeding risk among patients with non-valvular atrial …
Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation
PC Souverein, HA van den Ham… - British Journal of …, 2021 - Wiley Online Library
Aims The introduction of direct oral anticoagulants (DOACs) has broadened the treatment
arsenal for nonvalvular atrial fibrillation, but observational studies on the benefit–risk …
arsenal for nonvalvular atrial fibrillation, but observational studies on the benefit–risk …
Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation
M Ujeyl, I Köster, H Wille, T Stammschulte… - European journal of …, 2018 - Springer
Purpose The pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF)
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants
S Halvorsen, W Ghanima, I Fride Tvete… - European Heart …, 2017 - academic.oup.com
Aims We aimed to evaluate bleeding risk in clinical practice in patients with atrial fibrillation
(AF) being prescribed dabigatran, rivaroxaban, or apixaban compared with warfarin …
(AF) being prescribed dabigatran, rivaroxaban, or apixaban compared with warfarin …
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
GYH Lip, A Keshishian, S Kamble… - Thrombosis and …, 2016 - thieme-connect.com
In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs)
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …
[HTML][HTML] Discontinuation risk comparison among 'real-world'newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
GYH Lip, X Pan, S Kamble, H Kawabata, J Mardekian… - PLoS …, 2018 - journals.plos.org
Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF)
patients to an increased risk of stroke. This study describes the real-world discontinuation …
patients to an increased risk of stroke. This study describes the real-world discontinuation …
Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study
SH Hohnloser, E Basic, M Nabauer - Clinical Research in Cardiology, 2017 - Springer
Background Non-vitamin K antagonist oral anticoagulants (NOACs) are at least as effective
and safe as vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). All …
and safe as vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). All …